Stephen B. Shrewsbury

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Sebahattin Çirak, Virginia Arechavala‐Gomeza, Michela Guglieri et al. · The Lancet · 2011 · 862 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Safety and Pharmacokinetics of Dihydroergotamine Mesylate Administered Via a Novel (Tempo™) Inhaler

Stephen B. Shrewsbury, Robert O. Cook, Glyn Taylor et al. · Headache The Journal of Head and Face Pain · 2007 · 76 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A Randomized, Double Blind, Placebo‐Controlled Study of MAP0004 in Adult Patients With Migraine

Sheena K. Aurora, Todd D. Rozen, Shashidhar Kori et al. · Headache The Journal of Head and Face Pain · 2009 · 54 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy

Peter Sazani, Kirk P. Van Ness, Doreen L. Weller et al. · International Journal of Toxicology · 2011 · 49 citations

Pharmacy, Pharmacology, Toxicology +17

Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism

Robert O. Cook, Stephen B. Shrewsbury, Nabih M. Ramadan · Headache The Journal of Head and Face Pain · 2009 · 46 citations

Medicine, Pharmacology, Pharmacotherapy +17